IPO - Elicio Therapeutics, Inc.

Form Type: 424B5

Filing Date: 2025-01-30

Corporate Action: Ipo

Type: New

Accession Number: 000119312525016368

Filing Summary: Elicio Therapeutics, Inc. is offering 1,261,830 shares of common stock alongside common warrants to purchase an equivalent number of shares. Each common share is priced at $7.925, including a warrant with an exercise price of $7.80. The common warrants are immediately separable and will expire five years from issuance. The offering aims to raise approximately $10 million and will be managed by H.C. Wainwright & Co., LLC, which will receive 7% of gross proceeds as fees. Elicio, a clinical-stage biotech firm, focuses on immunotherapy development for cancer and infectious diseases, utilizing its proprietary Amphiphile technology targeting lymph nodes to induce robust T cell responses. The company anticipates that the offering's proceeds will support working capital and general corporate purposes. The common stock is traded on the Nasdaq under the symbol 'ELTX.' The delivery of these securities is expected around January 30, 2025, pending customary closing conditions.

Document Link: View Document